BioXcel Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BioXcel Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q2 2024.
  • BioXcel Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$17.3M, a 67% increase year-over-year.
  • BioXcel Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$110M, a 43.9% increase year-over-year.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$172M, a 7.6% decline from 2022.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$160M, a 49.3% decline from 2021.
  • BioXcel Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$107M, a 29.9% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$110M -$17.3M +$35.1M +67% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$145M -$24.2M +$27M +52.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$172M -$19.9M +$33M +62.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$205M -$48.3M -$9.31M -23.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$195M -$52.4M -$16.1M -44.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$179M -$51.2M -$19.7M -62.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$160M -$52.9M -$26.8M -102% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$133M -$39M -$12.2M -45.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$121M -$36.3M -$8.68M -31.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$112M -$31.5M -$5.1M -19.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$107M -$26.1M -$5.03M -23.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$102M -$26.8M -$2.04M -8.25% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$99.9M -$27.6M -$6.18M -28.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$93.7M -$26.4M -$11.4M -75.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$82.3M -$21.1M -$12.7M -151% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$69.6M -$24.8M -$15.6M -171% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$54M -$21.4M -$12.8M -148% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$41.2M -$15M -$7.58M -102% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$33.6M -$8.41M -$1.1M -15% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$32.5M -$9.13M -$4.02M -78.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$28.5M -$8.64M -$5.39M -166% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$23.1M -$7.42M -$3.13M -73.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$20M -$7.31M -$4.79M -190% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$15.2M -$5.12M -$4.2M -458% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$11M -$3.24M -$2.68M -474% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$8.29M -$4.29M -$3.76M -710% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$4.54M -$2.53M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$917K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$565K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$529K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.